RecruitingNot ApplicableNCT06382493

Tegoprazan-containing Sequential for H. Pylori

Efficacy of Tegoprazan-containing Sequential Therapy Compared to Proton Pump Inhibitor-based Eradication in South Korea, a Region With High Antimicrobial Resistance: A Prospective Randomized Single Tertiary Center Study

Sponsor

Seoul National University Bundang Hospital

Enrollment

400 participants

Start Date

Feb 1, 2021

Study Type

INTERVENTIONAL

Conditions

Helicobacter Pylori Infection

Summary

As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential eradication therapy

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Patients who had H. pylori infection proved by positive test result of urea breath test (UBT), rapid urase test or pathologic examination (warthin-giemsa staining)

Exclusion Criteria5

congestive heart failure, NYHA III or IV
end-stage renal disease
alcoholics
drug abusers
pregnant or nursing women

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTegoprazan-containing sequential H. pylori eradication therapy

tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy

DRUGEsomeprazole-containing sequential H. pylori eradication therapy

Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)